Aarti Pharmalabs Limited has informed the Exchange about Credit Rating
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs Limited has received a credit rating upgrade from CRISIL Ratings for its long-term bank loan facilities, effective July 17, 2025. The rating was upgraded from 'Crisil A+/Positive' to 'Crisil AA-/Stable', covering total bank loan facilities of Rs. 700 crore. The facilities include cash credit lines across six banks (Kotak Mahindra, SBI, Axis Bank, Citi Bank, Standard Chartered, IDBI Bank) at Rs. 75 crore each, a Rs. 100 crore long-term loan from Citi Bank, and proposed fund-based and long-term bank facilities aggregating Rs. 150 crore. The stable outlook suggests CRISIL expects the company's credit profile to remain consistent over the medium term.
This upgrade signals improved creditworthiness and stronger financial health, which may lower the company's future borrowing costs and boost investor confidence. Positive for shareholders as it reflects better financial stability.